India Pharma Outlook Team | Wednesday, 13 August 2025
US pharmaceutical giant Eli Lilly stepped up competition with rival Danish drugmaker Novo Nordisk on Wednesday by introducing its popular diabetes medication Mounjaro in the Indian market. KwikPen is a single patient use prefilled pen intended for once weekly treatment.
The pen will cost Rs 14,000 for a 2.5 mg dose, Rs 17,500 for a 5 mg dose, Rs 22,000 for 7.5 mg and 10 mg, and Rs 27,500 for 12.5 mg and 15 mg dose. It will be available in six dosing strengths.According to the business, this will enable medical practitioners to tailor treatment regimens to each patient's specific requirements.
“The launch of Mounjaro KwikPen marks a step forward in the care of type 2 diabetes and obesity, offering a more convenient approach to medication administration." said Winselow Tucker, President and General Manager, Lilly India. “We believe this innovation will support healthcare professionals in delivering more personalized and effective treatment plans, helping to improve outcomes and advance the quality of care for people living with these serious diseases.”
Reiterating that Mounjaro is a prescription-only drug that must be taken exclusively under the supervision of a licensed healthcare providers, the business has issued a warning against its cosmetic use. "It should not be used for cosmetic weight loss as it is not approved for that purpose."
Also Read: Glenmark Becomes First Indian Company to Launch Biosimilar of Liraglutide
“Patients are advised to consult their healthcare professional to determine whether Mounjaro is appropriate for their individual needs,” it further said. Mounjaro is the first and only dual GIP (glucose- dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, indicated as an adjunct to diet and exercise for the treatment of Type 2 diabetes and chronic weight management in adults with obesity or overweight, with one weight-related comorbidity.
